Grouped product items

SKU

Size

Availability

Price

Qty

N411994-1mg

1mg

Available within 4-8 weeks(?)

$159.90

N411994-5mg

5mg

Available within 4-8 weeks(?)

$664.90

N411994-10mg

10mg

Available within 4-8 weeks(?)

$1,196.90

Basic Description

Product Name	Nivolumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1/PD-1/CD279, >95%, high purity, Human IgG4SP
Synonyms	CID 167682467 \| hPD-1 \| Protein PD-1
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	PDCD1/PD-1/CD279
Application	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	Antibody of programmed cell death 1 (CD279)
Product Description	Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG4SP
Light Chain Type	kappa
SDS-PAGE	26.4 kDa (Light Chain) & 53.3 kDa (Heavy Chain), under reducing conditions; 178.6 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	946414-94-4

Images

Nivolumab (anti-PD-1) (N411994) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Nivolumab (anti-PD-1) (N411994). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Nivolumab (anti-PD-1) (N411994) - SEC
The purity of Nivolumab (anti-PD-1) (N411994) is more than 95% verified by HPLC.

Associated Targets(Human)

PDCD1 Tclin Programmed cell death protein 1 (0 Activities)

Discover Target: PDCD1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PDCD1 Tclin Programmed cell death protein 1 (14 Activities)

Discover Target: PDCD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Database links

IMGT/mAb-DB	424
Wikipedia	nivolumab
Reactome Reaction	R-HSA-9679421
Reactome Drug	R-ALL-9679411
PEP	nivolumab

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
ZJ23F0800920	Certificate of Analysis	Aug 26, 2023	N411994
ZJ23F0800919	Certificate of Analysis	Aug 26, 2023	N411994
ZJ23F0800918	Certificate of Analysis	Aug 26, 2023	N411994

FAQs and Articles

FAQ

Flow cytometry protocol

Categories: Protocols

Tags:

Antibodies Flow Cytometry Flow Antibodies Reactive dyes Indirect antibody labelling

References

1. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer.. Discov Med, 14 (77): (229-36). [PMID:23114578] [10.1021/op500134e]
2. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy.. Blood, 121 (5): (734-44). [PMID:23223433] [10.1021/op500134e]
3. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.. Curr Oncol Rep, 15 (2): (98-104). [PMID:23263823] [10.1021/op500134e]
4. Hamid O, Carvajal RD. (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.. Expert Opin Biol Ther, 13 (6): (847-61). [PMID:23421934] [10.1021/op500134e]
5. Intlekofer AM, Thompson CB. (2013) At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.. J Leukoc Biol, 94 (1): (25-39). [PMID:23625198] [10.1021/op500134e]
6. Callahan MK, Wolchok JD. (2013) At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.. J Leukoc Biol, 94 (1): (41-53). [PMID:23667165] [10.1021/op500134e]
7. O'Sullivan Coyne G, Madan RA, Gulley JL. (2014) Nivolumab: promising survival signal coupled with limited toxicity raises expectations.. J Clin Oncol, 32 (10): (986-8). [PMID:24590655] [10.1021/op500134e]
8. Luke JJ, Ott PA. (2015) PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.. Oncotarget, 6 (6): (3479-92). [PMID:25682878] [10.1021/op500134e]
9. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.. N Engl J Med, 372 (21): (2006-17). [PMID:25891304] [10.1021/op500134e]
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.. N Engl J Med, 373 (1): (23-34). [PMID:26027431] [10.1021/op500134e]
11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al.. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.. N Engl J Med, 373 (19): (1803-13). [PMID:26406148] [10.1021/op500134e]
12. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.. N Engl J Med, 378 (14): (1277-1290). [PMID:29562145] [10.1021/op500134e]
13. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy.. Nat Rev Cancer, 12 (4): (252-64). [PMID:22437870] [10.1021/op500134e]
14. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy.. Cancer Cell, 27 (4): (450-61). [PMID:25858804] [10.1021/op500134e]
15. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e]
16. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e]
17. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e]
18. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e]
19. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e]
20. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] [10.1021/op500134e]
21. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365]
22. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] [10.1021/acs.jmedchem.0c00574]
23. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902]
24. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038]
25. Fife, Brian T BT and Pauken, Kristen E KE.. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance.. Annals of the New York Academy of Sciences, [PMID:21276005]
26. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127]
27. Cheng, Xiaoxiao X and 18 more authors.. (2013) Structure and interactions of the human programmed cell death 1 receptor.. The Journal of biological chemistry, (26): [PMID:23417675]
28. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552]
29. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857]
30. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296]
31. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663]
32. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966]
33. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004]
34. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Nivolumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1/PD-1/CD279, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)

Basic Description

Product Properties

Images

Associated Targets(Human)

Mechanisms of Action

Database links

Certificates

Certificate of Analysis(COA)

Related Documents

FAQs and Articles

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator

SKU	Size	Availability	Price
N411994-1mg	1mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$159.90
N411994-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$664.90
N411994-10mg	10mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$1,196.90